Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
19 hedge funds and large institutions have $477K invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 14 closing their positions.
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
37% less funds holding
Funds holding: 30 → 19 (-11)
78% less capital invested
Capital invested by funds: $2.14M → $477K (-$1.66M)
79% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$16K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$593 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$68 |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$19 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$131K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$38K |
| 3 |
State Street
Boston,
Massachusetts
|
-$32K |
| 4 |
Bank of New York Mellon
New York
|
-$25K |
| 5 |
AI
Atom Investors
Austin,
Texas
|
-$24K |
ELOX Hedge Fund Activity: Q4 2022 in Review
19 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q4 2022, worth a combined $477K — down 78% from $2.14M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ELOX and 3 opened new positions — a net loss of 11 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $16K. The largest seller was Vanguard Group, cutting an estimated $131K.
- 19 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q4 2022, down from 30 in Q3 2022.
- Funds reported $477K of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 78% quarter-over-quarter.
- 3 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 14 closed out, a net change of -11 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Tower Research Capital (TRC), an estimated $16K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was Vanguard Group, an estimated $131K sold.
Based on aggregated 13F filings for Q4 2022.